Back

A 10-year follow-up study on diagnostic yield in families of sudden cardiac death patients

30 March 2025 (08:00 - 15:30)
Organised by: Logo
Congress Presentation Part of: Ventricular arrhythmias risk prediction Epidemiology, Prognosis, Outcome EHRA Premium Access EHRA 2025 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Miss Christine Louise Groenholdt

Copenhagen (Denmark)

5 More presentations in this session

Presentation thumbnail
Identification of patients with mitral annular disjunction and the highest risk of ventricular arrhythmias using advanced echocardiography tools
Professor L. Danilowicz-Szymanowicz (Gdansk, PL)
Abstract Slides Video
Presentation thumbnail
Non-invasive risk assessment and prediction of cardiac outcomes in patients with heart failure or myocardial infarction using deep learning method
Doctor J. Kim (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
The impact of length of antidepressant use on risk of sudden cardiac death
Doctor J. Mujkanovic (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Non-invasive electrocardiographic imaging to stratify risk of ventricular arrhythmia
Mr E. Ayauja Lopez (Barcelona, ES)
Abstract Slides Video
Presentation thumbnail
Long-term risk assessment in athletes with complex ventricular arrhythmias
Associate Professor M. Casella (Ancona, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Ventricular arrhythmias risk prediction

The Event

Event poster

EHRA 2025

30 March - 1 April 2025
You may be interested in
thumbnail
Congress Presentation
The role of post mortem genetic testing and family screening of young sudden cardiac death cases
thumbnail
Congress Presentation
RESCUED (REgistry for Sudden Cardiac and UnExpected Death): the German registry for families affected by sudden cardiac death in the young
thumbnail
Congress Presentation
Prognostic implications of family screening in Dilated and Arrhythmogenic Cardiomyopathies

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources